echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > R & D Daily: moxifloxacin hydrochloride injection approved for marketing

    R & D Daily: moxifloxacin hydrochloride injection approved for marketing

    • Last Update: 2020-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Skyrizi's head to head phase 3 research reached the end point; Zhendong pharmaceutical's paracetamol tablet has been evaluated; Huabang pharmaceutical's bensulfobertastine tablet has passed the consistency evaluation; nature found that T cells can be used to "target" the characteristics of EB virus We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On the 14th, Aberdeen announced that skyrizi, its new anti-inflammatory drug, had defeated Novartis cosentityx to reach the primary end point and all secondary end points in the head-to-head phase 3 clinical study (nct03478787) for the treatment of plaque psoriasis Recently, abeona therapeutics announced that it has obtained the approval of the institutional review committee from Stanford University to launch the critical phase III trial of vital to evaluate the treatment of recessive genetic dystrophic epidermolysis bullosa with eb-101 A few days ago, acasti pharmaceutical company (Kapre) missed the main end point in the phase III Trilogy 1 study on the treatment of severe hypertriglyceridemia North China Pharmaceutical Co., Ltd announced on May 15 that it has recently received the approval document for supplementary drug application for Amoxicillin Capsules (0.5g, 0.25g) and metformin hydrochloride tablets (0.5g) approved and issued by the State Drug Administration, which has passed the quality and efficacy consistency evaluation of generic drugs On May 15, Zhendong pharmaceutical announced that its wholly-owned subsidiary, antbio, had received the approval document for supplementary drug application (approval document No.: 2020b02005) on 0.5g paracetamol tablets approved and issued by the State Food and drug administration, which passed the consistency evaluation of quality and efficacy of generic drugs On May 15, Peking University Pharmaceutical announced that the company had received the registration approval of moxifloxacin hydrochloride injection approved and issued by the State Food and drug administration Recently, Huabang pharmaceutical has been approved as the first enterprise in China to obtain the registration approval with the new 4 categories of bensulfobertastine tablets, which are deemed to have passed the consistency evaluation Today, the FDA panel voted against the listing application of nktr-181 (loxicodegol), nektar's mu opioid receptor agonist, by a rare 27:0 vote Ultragenyx Pharmaceutical Co., Ltd and its partner kylin announced recently that they have submitted to FDA crysvita (burosumab) a license application for supplementary biological products for the treatment of hypophosphatemia related to FGF23 and phosphate urothelioma that cannot be radically removed or located Researchers at the University of Pennsylvania have designed a new proton flash radiotherapy system, which can precisely control the beam flux in milliseconds and effectively avoid damage to normal tissues while killing cancer cells The report was recently published in the International Journal of radiation oncology, biology, and physics Recently, researchers from University College London, published in the international journal immunology, revealed how a special kind of immune cells can be activated to kill cancer cells through research on mice, which may help develop new anti-cancer therapies Recently, in a research report published in the international journal Nature, scientists from Stanford University found immune cells unable to get rid of the virus in the brain of patients with late Alzheimer's disease and the cerebrospinal fluid of patients with Alzheimer's disease These amazing numbers of T cells can be used to "target" the characteristics of EB virus.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.